Malignant Pleural Mesothelioma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of malignant pleural mesothelioma (MPM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of MPM for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s MPM forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with MPM per year?
- Of all people with MPM, how many in each country in the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MPM over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts nine MPM patient populations, as follows:
- Diagnosed metastatic recurrent incident cases
- Resectable drug-treatable prevalent cases
- Diagnosed first-line drug-treatable population
- Diagnosed prevalent cases
- Unresectable drug-treatable prevalent cases
- Resectable non-drug-treatable prevalent cases
- Diagnosed unresected incident cases
- Diagnosed incident cases
- Diagnosed resected incident cases
Note: Coverage may vary by country.
